Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1OP9

Complex of human lysozyme with camelid VHH HL6 antibody fragment

1OP9 の概要
エントリーDOI10.2210/pdb1op9/pdb
分子名称HL6 camel VHH fragment, Lysozyme C (3 entities in total)
機能のキーワードantigen-antibody complex, immunoglobulin, amyloid fibril formation inhibition, hydrolase
由来する生物種Camelus dromedarius (Arabian camel)
詳細
細胞内の位置Secreted: P61626
タンパク質・核酸の鎖数2
化学式量合計27759.94
構造登録者
主引用文献Dumoulin, M.,Last, A.M.,Desmyter, A.,Decanniere, K.,Canet, D.,Larsson, G.,Spencer, A.,Archer, D.B.,Sasse, J.,Muyldermans, S.,Wyns, L.,Redfield, C.,Matagne, A.,Robinson, C.V.,Dobson, C.M.
A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme
Nature, 424:783-788, 2003
Cited by
PubMed Abstract: Amyloid diseases are characterized by an aberrant assembly of a specific protein or protein fragment into fibrils and plaques that are deposited in various organs and tissues, often with serious pathological consequences. Non-neuropathic systemic amyloidosis is associated with single point mutations in the gene coding for human lysozyme. Here we report that a single-domain fragment of a camelid antibody raised against wild-type human lysozyme inhibits the in vitro aggregation of its amyloidogenic variant, D67H. Our structural studies reveal that the epitope includes neither the site of mutation nor most residues in the region of the protein structure that is destabilized by the mutation. Instead, the binding of the antibody fragment achieves its effect by restoring the structural cooperativity characteristic of the wild-type protein. This appears to occur at least in part through the transmission of long-range conformational effects to the interface between the two structural domains of the protein. Thus, reducing the ability of an amyloidogenic protein to form partly unfolded species can be an effective method of preventing its aggregation, suggesting approaches to the rational design of therapeutic agents directed against protein deposition diseases.
PubMed: 12917687
DOI: 10.1038/nature01870
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.86 Å)
構造検証レポート
Validation report summary of 1op9
検証レポート(詳細版)ダウンロードをダウンロード

252091

件を2026-04-15に公開中

PDB statisticsPDBj update infoContact PDBjnumon